Latest News

Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development

NOVELOS THERAPEUTICS CLOSES LAST TRANCHE IN $9 MILLION PRIVATE PLACEMENT

Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries

IMS Health to Launch Oncology Quantifier, Delivering Integrated Insights for Enhanced Market Measurement, Commercial Strategies

Simcyp Simulator aids in preclinical ADME assessment of Genentech compound

Conclusion of the Agreement on Apaziquone for Non-muscle invasive bladder cancer

The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS

Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab

University of Cambridge and Life Technologies Collaborate on Landmark High Throughput Sequencing Hub in United Kingdom

More news... | RSS Feed...

Most Viewed

FDA GRANTS ORPHAN DRUG DESIGNATION FOR TNFERADE(TM)

Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress

Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development

Bayer and Onyx Initiate Phase III Trial of Nexavar

ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG

The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

PRIMA BIOMED SECURES JAPANESE PATENT FOR CANCER VAC

Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer

Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)

Therapeutic Target

Cardiovascular

Dermatology

Endocrine and Metabolic

Gastroenterology

Genitourinary

Hematology

Immunology and Allergy

Infection

Musculoskeletal

Neurology

Obstetrics and Gynecology

Oncology

Ophthalmology

Psychiatry

Pulmonary

Categories

Deals and Alliances

Development

Financial Results

Financings

Intellectual Property

Regulatory

Press releases

Deals review

Headlines

PR Newswire